Pharmacodinamics (PD)
PD
Assessment of the PD profile of LNA-i-miR-221 was performed by reverse transcription quantitative PCR (RT‐qPCR) of miR-221 and CDKN1B in PBMCs isolated from patients at pre-dose (d1) and 24 h after LNA-miR-221 end treatment (d5). Figure Target modulation on PBMCs by LNA-miR-221 inhibitor. Expression levels of miR-221 and 